San Jose, California, June 5, 2018. Molecular Devices announced today the launch of the new SpectraMax® ABS and ABS Plus Microplate Readers that cover a wide range of absorbance-based applications such as ELISAs, microbial growth, and protein quantitation and can be easily integrated into full robotic systems.
The SpectraMax ABS Microplate Reader bridges the gap between the affordability of filter-based readers and the flexibility of monochromator-based systems. The SpectraMax ABS Plus Microplate Reader can run both cuvette-based and microplate reader applications on the same instrument.
Both readers have filterless monochromator flexibility that allows for selecting the exact wavelength for every assay. The 8-channel read head allows for fast read times which means a 96-well plate can be read in as little as five seconds. In addition, the industry leading SoftMax® Pro Data Acquisition and Analysis Software is included with both SpectraMax ABS readers and provides users with the ability to handle analysis requirements from simple endpoint assays to complex kinetic assays requiring custom calculations, meeting the needs of every researcher.
“We continue to expand on our high-quality line of microplate reader platforms with a new line of absorbance microplate readers”, said Greg Milosevich, President of Molecular Devices. “The ABS Plus reader comes standard with our patented PathCheck Technology which enables consistent results across a 96- or 384-well plate despite volume differences that may occur due to pipetting errors.”
About Molecular Devices, LLC
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.
For more information, visit: